Vaccines

Aldevron and Ginkgo Bioworks Collaboration Yields mRNA Manufacturing Enhancement

August 12, 2021

A collaboration between Aldevron and Ginkgo Bioworks has resulted in a manufacturing enhancement that can improve production of an enzyme used for mRNA therapeutics.

Moderna Plans to Build mRNA Vaccine Manufacturing Facility in Canada

August 12, 2021

Moderna will build an mRNA vaccine manufacturing facility in Canada to provide access to domestically manufactured vaccines against respiratory viruses.

EMA Recommends Including Adverse Reaction Warning to Janssen COVID-19 Vaccine

August 09, 2021

The agency’s Pharmacovigilance Risk Assessment Committee recommended updating the product information for Janssen’s COVID-19 vaccine to list immune thrombocytopenia as an adverse reaction.

EMA’s PRAC Requests Additional Data on Guillain-Barré Syndrome in COVID-19 Vaccine

August 09, 2021

EMA’s Pharmacovigilance Risk Assessment Committee has requested more data for its evaluation of reports of Guillain-Barré syndrome after vaccination.

CHMP Approves Manufacturing Scale-Up for Spikevax

August 04, 2021

EMA’s CHMP has approved the increased manufacturing capacity and supply of Moderna’s COVID-19 vaccine active substance in its US manufacturing site.

Analysis Demonstrates No Increased Incidence of Thrombosis with TTS After Vaxzevria Second Dose

August 04, 2021

A global safety database analysis has demonstrated no increased incidence of thrombosis with TTS after the second dose of Vaxzevria.

Nitric Oxide Nasal Spray for COVID-19 to Be Distributed to India and Other Asia Markets

August 04, 2021

Glenmark Pharmaceuticals has partnered with SaNOtize to manufacture, market, and distribute NONS to India, Singapore, Malaysia, Hong Kong, and more.

EMA Starts Rolling Review of Sanofi’s COVID-19 Vaccine

July 29, 2021

EMA's CHMP has taken the decision to start a rolling review of Vidprevtyn—Sanofi Pasteur’s COVID-19 vaccine.

FDA Approves Merck’s 15-Valent Pneumococcal Vaccine

July 27, 2021

Merck announced that FDA approved Vaxneuvance for active immunization for the prevention of invasive pneumococcal disease.

Meissa’s Intranasal COVID-19 Vaccine Yields Promising Preclinical Data

July 27, 2021

Meissa Vaccines’s MV-014-212, an intranasal recombinant live attenuated COVID-19 vaccine, induced mucosal and systemic antibodies against SARS-CoV-2 and two variants of concern.